<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02844309</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2015004-EC-2</org_study_id>
    <nct_id>NCT02844309</nct_id>
  </id_info>
  <brief_title>The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM</brief_title>
  <acronym>BDH-WM02</acronym>
  <official_title>The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficiency of an oral regimen in newly diagnosed
      Waldenström macroglobulinemia: thalidomide plus cyclophosphamide and dexamethasone following
      by thalidomide and prednisone maintenance therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled patients will accept maximum 8 cycles of thalidomide plus cyclophosphamide and
      dexamethasone. if a partial remission response or better is achieved, thalidomide plus
      prednisone maintenance therapy will be given for no more than two years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progress-free survival</measure>
    <time_frame>up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Waldenström Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Thalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>thalidomide 50-150mg per night</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>thalidomide 50-150 mg per night</description>
    <arm_group_label>Thalidomide</arm_group_label>
    <other_name>Thal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged &gt;=18 years

          2. diagnosed with WM

          3. Untreated or mild treated without standard regimens,especially untreated with
             rituximab and/or bortezomib

          4. symptom patients

          5. with life-expectancy more than 3 months.

        Exclusion Criteria:

          1. diagnosed with other malignancies outside B-NHL within one year(including active
             centre neural system lymphoma)

          2. Transformed lymphoma

          3. liver or renal function lesion unrelated to lymphoma

          4. serious complications such as uncontrolled diabetes,gastric ulcer or other serious
             angiocardiopathy determined by the physician

          5. HIV positive or active HBV infection or other uncontrolled systematic infection

          6. clinical central nervous dysfunction

          7. serious surgery within 30 days

          8. pregnancy or baby nursing period or un-contracepted child-bearing period woman;

          9. allergy to the trail drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuhua Yi, Doc</last_name>
    <role>Principal Investigator</role>
    <affiliation>institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuhua Yi, Doc</last_name>
    <phone>86-22-23909106</phone>
    <email>yishuhua@ihcams.ac.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lugui Qiu, Doc</last_name>
    <phone>86-22-23909172</phone>
    <email>qiulg@ihcams.ac.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shuhua Yi</name>
      <address>
        <city>Tianjin</city>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhua Yi, Doc</last_name>
      <phone>86-22-23909106</phone>
      <email>yishuhua@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lugui Qiu, Doc</last_name>
      <phone>86-22-23909172</phone>
      <email>qiulg@ihcams.ac.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2016</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Yi Shuhua</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>whether to publish primary data is dependent on the local law</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

